Clinical Trial: The Benefits of Transcranial Photobiomodulation in Lewy Body Disease

U.S., May 23 -- ClinicalTrials.gov registry received information related to the study (NCT07602296) titled 'The Benefits of Transcranial Photobiomodulation in Lewy Body Disease' on May 15.

Brief Summary: Lewy body disease (LBD) is the second leading cause of progressive neurodegenerative dementia. Characterised by a complex clinical picture combining cognitive, motor and behavioural symptoms, it is subject to a high rate of misdiagnosis and lacks a fully effective curative or symptomatic treatment. The LEWY-LIGHT project aims to evaluate, for the first time in LBD, an innovative non-pharmacological approach: transcranial photobiomodulation (PBM). This non-invasive and safe technique uses red/infrared light to stimulate brain cell activity ...